The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
Harbour BioMed brings advanced antibody discovery platforms to the table
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
Subscribe To Our Newsletter & Stay Updated
